Drugs /

pentostatin

Back to Drugs List

Overview

Generic Name(s):
pentostatin
Trade Name(s):
Nipent
NCI Definition [1]:
A purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2'-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes. (NCI04)

Clinical Trials

View Clinical Trials for pentostatin

Pentostatin has been investigated in 4 clinical trials, of which 3 are open and 1 is closed. Of the trials investigating pentostatin, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open).

CD19 Expression, CD22 Expression, and DNTT Expression are the most frequent biomarker inclusion criteria for pentostatin clinical trials.

Chronic myeloid leukemia, multiple myeloma, and acute lymphoblastic leukemia are the most common diseases being investigated in pentostatin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pentostatin
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Pentostatin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pentostatin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Nipent, pentostatina, co-vidarabine, 16505, deoxycoformycin 02, (r)-3-(2-deoxy-beta-d-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol, lederle brand of pentostatin, ci-825, 53910-25-1, pentostatin, co-vidarabine, dcf, pentostatin (product), 218321, pentostatine, (r)-3-(2-deoxy-beta-d-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol, pd-81565, co vidarabine, ci825, 2' deoxycoformycin, pentostatinum, 2'-deoxycoformycin, 247520, ci 825, wyeth brand of pentostatin, imidazo(4,5-d)(1,3)diazepin-8-ol, 3-(2-deoxy-beta-d-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (r)-, pentostatin, warner-lambert brand of pentostatin, co-vidarabine, covidarabine, deoxycoformycin, 2'-deoxycoformycin, prasfarma brand of pentostatin, 52325, (r)-3-(2-deoxy-.beta.-d-erythro-pentofuranosyl)-3,6,7, 8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol, pentostatin (substance), supergen brand of pentostatin, pentostatin [chemical/ingredient], pentostatine, deoxycoformycin
Drug Categories [2]:
Antimetabolites
NCIT ID [1]:
C732
SNOMED ID [1]:
F-61A2B

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.